Tributary Capital Management LLC Purchases 1,634 Shares of Balchem Co. (NASDAQ:BCPC)

Tributary Capital Management LLC boosted its stake in shares of Balchem Co. (NASDAQ:BCPC) by 1.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 136,255 shares of the basic materials company’s stock after purchasing an additional 1,634 shares during the period. Balchem makes up about 1.7% of Tributary Capital Management LLC’s portfolio, making the stock its 22nd biggest position. Tributary Capital Management LLC’s holdings in Balchem were worth $22,209,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently bought and sold shares of the company. Inspire Investing LLC boosted its holdings in shares of Balchem by 2.7% in the 3rd quarter. Inspire Investing LLC now owns 2,348 shares of the basic materials company’s stock valued at $413,000 after acquiring an additional 62 shares during the last quarter. Hsbc Holdings PLC lifted its holdings in Balchem by 1.5% during the second quarter. Hsbc Holdings PLC now owns 4,915 shares of the basic materials company’s stock valued at $757,000 after purchasing an additional 75 shares in the last quarter. Atomi Financial Group Inc. lifted its stake in shares of Balchem by 6.1% in the third quarter. Atomi Financial Group Inc. now owns 1,674 shares of the basic materials company’s stock worth $295,000 after buying an additional 96 shares in the last quarter. Xponance Inc. lifted its stake in shares of Balchem by 5.2% in the second quarter. Xponance Inc. now owns 2,046 shares of the basic materials company’s stock worth $315,000 after buying an additional 102 shares in the last quarter. Finally, Heritage Family Offices LLP lifted its stake in shares of Balchem by 8.3% in the fourth quarter. Heritage Family Offices LLP now owns 1,420 shares of the basic materials company’s stock worth $231,000 after buying an additional 109 shares in the last quarter. Hedge funds and other institutional investors own 87.91% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. HC Wainwright lifted their target price on shares of Balchem from $185.00 to $190.00 and gave the stock a “buy” rating in a research note on Monday, November 4th. StockNews.com upgraded shares of Balchem from a “hold” rating to a “buy” rating in a report on Monday, October 28th.

Balchem Stock Down 1.2 %

Shares of Balchem stock opened at $160.23 on Friday. Balchem Co. has a 52-week low of $137.69 and a 52-week high of $186.03. The company has a 50 day moving average of $168.92 and a 200 day moving average of $170.82. The company has a quick ratio of 1.90, a current ratio of 2.98 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $5.21 billion, a P/E ratio of 43.07, a P/E/G ratio of 4.36 and a beta of 0.69.

Balchem Increases Dividend

The firm also recently declared an annual dividend, which was paid on Friday, January 17th. Investors of record on Thursday, December 26th were given a $0.87 dividend. This is an increase from Balchem’s previous annual dividend of $0.79. The ex-dividend date of this dividend was Thursday, December 26th. This represents a yield of 0.4%. Balchem’s dividend payout ratio is 23.39%.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.